RASP (Actavia Life Sciences) Forward PE Ratio: 0.00 (As of Jul. 05, 2026)


What is Actavia Life Sciences Forward PE Ratio?

Actavia Life Sciences RASP -87.50% Forward PE Ratio is 0.00 as of Jul. 05, 2026.

Actavia Life Sciences's Forward PE Ratio for today is 0.00.

Actavia Life Sciences's PE Ratio without NRI for today is 0.00.

Actavia Life Sciences's PE Ratio (TTM) for today is 0.00.

Actavia Life Sciences  (OTCPK:RASP) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Actavia Life Sciences Forward PE Ratio Related Terms

Actavia Life Sciences Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences Forward PE Ratio Chart

Actavia Life Sciences Annual Data
Trend
Forward PE Ratio

Actavia Life Sciences Quarterly Data
Forward PE Ratio

RASP vs BWV, FNCH, CWBR: Forward PE Ratio Comparison

For the Biotechnology subindustry, Actavia Life Sciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actavia Life Sciences Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's Forward PE Ratio falls into.


Actavia Life Sciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Actavia Life Sciences (RASP) has a Forward PE Ratio of 0.00 as of Jul. 05, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' Forward PE Ratio too high?
Actavia Life Sciences' current Forward PE Ratio is 0.00.
How does Actavia Life Sciences' Forward PE Ratio compare to BWV and FNCH?
Actavia Life Sciences' Forward PE Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median Forward PE Ratio is 22.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.47, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Actavia Life Sciences and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actavia Life Sciences's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Forward PE Ratio is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.